FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794178081> ?p ?o ?g. }

• W2794178081 abstract "ABSTRACT Botulinum neurotoxin (BoNT) is the causative agent of botulism and a widely used pharmaceutical to treat a variety of neurological diseases. BoNTs are 150-kDa protein toxins organized into heavy chain (HC) and light chain (LC) domains linked by a disulfide bond. The HC selectively binds to neurons and aids cell entry of the enzymatically active LC. There are seven immunological BoNT serotypes (A to G); each serotype includes genetic variants, termed subtypes. Only two subtypes, BoNT/A1 and BoNT/B1, are currently used as therapeutics. BoNT serotype A (BoNT/A) subtypes A2 to A8 show distinct potency, duration of action, and pathology relative to BoNT/A1. Specifically, BoNT/A3 possesses shorter duration of action and elicits distinct symptoms in mice at high toxin doses. In this report, we analyzed the roles of LC and HC of BoNT/A3 for duration of action, neuronal cell entry, and mouse pathology by using clostridium-derived recombinant hybrid BoNTs consisting of reciprocal LC and HC (BoNTA1/A3 and BoNTA3/A1). Hybrid toxins were processed in their expression host to a dichain BoNT consisting of LC and HC linked via a disulfide bond. The LC and HC defined BoNT potency in mice and BoNT toxicity for cultured neuronal cells, while the LC defined the duration of BoNT action in cell and mouse models. Protein alignment identified a previously unrecognized region within the LC subtype A3 (LC/A3) relative to the other LC serotype A (LC/A) subtypes (low primary acid homology [LPH]) that correlated to intracellular LC localization. This study shows the utility of recombinant hybrid BoNTs with new therapeutic potential, while remaining sensitive to antitoxins and therapies to native BoNT. IMPORTANCE Botulinum neurotoxins are the most potent protein toxins for humans and potential bioterrorism threats, but they are also widely used as pharmaceuticals. Within the large family of BoNTs, only two subtypes are currently used as pharmaceuticals, with a large number of BoNT subtypes remaining as untapped potential sources for unique pharmaceuticals. Here, two recombinant hybrid toxins were engineered, consisting of domains from two BoNT subtypes that possess distinct duration of action and activity in human neurons and mice. We define the functional domains responsible for BoNT action and demonstrate creation of functional hybrid BoNTs with new therapeutic potential, while remaining sensitive to antitoxins and therapies to native BoNT." @default.
• W2794178081 created "2018-03-29" @default.
• W2794178081 creator A5021300055 @default.
• W2794178081 creator A5042947326 @default.
• W2794178081 creator A5052680650 @default.
• W2794178081 creator A5063253432 @default.
• W2794178081 creator A5064759142 @default.
• W2794178081 creator A5071228653 @default.
• W2794178081 creator A5071953944 @default.
• W2794178081 creator A5076200634 @default.
• W2794178081 date "2018-05-02" @default.
• W2794178081 modified "2023-09-29" @default.
• W2794178081 title "The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes" @default.
• W2794178081 cites W1483437518 @default.
• W2794178081 cites W1542852461 @default.
• W2794178081 cites W1555110619 @default.
• W2794178081 cites W1555460174 @default.
• W2794178081 cites W1596470233 @default.
• W2794178081 cites W1831356709 @default.
• W2794178081 cites W1964883374 @default.
• W2794178081 cites W1965137822 @default.
• W2794178081 cites W1965611434 @default.
• W2794178081 cites W1968774198 @default.
• W2794178081 cites W1973897713 @default.
• W2794178081 cites W1986950166 @default.
• W2794178081 cites W1987243111 @default.
• W2794178081 cites W1998208440 @default.
• W2794178081 cites W2007797957 @default.
• W2794178081 cites W2008558256 @default.
• W2794178081 cites W2029182482 @default.
• W2794178081 cites W2031187614 @default.
• W2794178081 cites W2041813390 @default.
• W2794178081 cites W2045061466 @default.
• W2794178081 cites W2045544140 @default.
• W2794178081 cites W2047821263 @default.
• W2794178081 cites W2050045956 @default.
• W2794178081 cites W2055043387 @default.
• W2794178081 cites W2061022231 @default.
• W2794178081 cites W2065332506 @default.
• W2794178081 cites W2069179176 @default.
• W2794178081 cites W2075826540 @default.
• W2794178081 cites W2078541439 @default.
• W2794178081 cites W2089899426 @default.
• W2794178081 cites W2092941891 @default.
• W2794178081 cites W2096738649 @default.
• W2794178081 cites W2098776203 @default.
• W2794178081 cites W2099781604 @default.
• W2794178081 cites W2101211619 @default.
• W2794178081 cites W2111510216 @default.
• W2794178081 cites W2115295036 @default.
• W2794178081 cites W2116651374 @default.
• W2794178081 cites W2133895941 @default.
• W2794178081 cites W2135614898 @default.
• W2794178081 cites W2166825283 @default.
• W2794178081 cites W2167510077 @default.
• W2794178081 cites W2187100152 @default.
• W2794178081 cites W2194986993 @default.
• W2794178081 cites W2208933232 @default.
• W2794178081 cites W2225433666 @default.
• W2794178081 cites W249987 @default.
• W2794178081 cites W2578933961 @default.
• W2794178081 cites W2598060151 @default.
• W2794178081 cites W2623442987 @default.
• W2794178081 cites W2755862584 @default.
• W2794178081 cites W2778849518 @default.
• W2794178081 cites W4210725983 @default.
• W2794178081 cites W52320979 @default.
• W2794178081 cites W827511652 @default.
• W2794178081 doi "https://doi.org/10.1128/mbio.00089-18" @default.
• W2794178081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5874905" @default.
• W2794178081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29588398" @default.
• W2794178081 hasPublicationYear "2018" @default.
• W2794178081 type Work @default.
• W2794178081 sameAs 2794178081 @default.
• W2794178081 citedByCount "46" @default.
• W2794178081 countsByYear W27941780812018 @default.
• W2794178081 countsByYear W27941780812019 @default.
• W2794178081 countsByYear W27941780812020 @default.
• W2794178081 countsByYear W27941780812021 @default.
• W2794178081 countsByYear W27941780812022 @default.
• W2794178081 countsByYear W27941780812023 @default.
• W2794178081 crossrefType "journal-article" @default.
• W2794178081 hasAuthorship W2794178081A5021300055 @default.
• W2794178081 hasAuthorship W2794178081A5042947326 @default.
• W2794178081 hasAuthorship W2794178081A5052680650 @default.
• W2794178081 hasAuthorship W2794178081A5063253432 @default.
• W2794178081 hasAuthorship W2794178081A5064759142 @default.
• W2794178081 hasAuthorship W2794178081A5071228653 @default.
• W2794178081 hasAuthorship W2794178081A5071953944 @default.
• W2794178081 hasAuthorship W2794178081A5076200634 @default.
• W2794178081 hasBestOaLocation W27941780811 @default.
• W2794178081 hasConcept C10389963 @default.
• W2794178081 hasConcept C153911025 @default.
• W2794178081 hasConcept C159047783 @default.
• W2794178081 hasConcept C159654299 @default.
• W2794178081 hasConcept C169760540 @default.
• W2794178081 hasConcept C185592680 @default.
• W2794178081 hasConcept C202751555 @default.
• W2794178081 hasConcept C203014093 @default.
• W2794178081 hasConcept C2777010668 @default.

• next